Darolutamide boosts survival in nonmetastatic prostate cancer
(HealthDay)—For men with nonmetastatic, castration-resistant prostate cancer, the risk for death is significantly lower for those receiving darolutamide versus placebo, according to a study published in the Sept. 10 issue ...